SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon GammaArticle Published on 2024-06-192024-09-05 Journal: Vaccines [Category] update2024, [키워드] cytokine profile Glatiramer acetate immunomodulation mRNA vaccines multiple sclerosis Ocrelizumab Protein-based vaccines sphingosine 1-phostphate receptor modulators Vaccination strategies Viral vector vaccines [DOI] 10.3390/vaccines12060684 PMC 바로가기 [Article Type] Article
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reportsReview Paper Published on 2023-04-042024-09-04 Journal: Science (New York, N.Y.) [Category] 대상포진, [키워드] adverse effects Glatiramer acetate Interferon beta-1a multiple sclerosis systematic review [DOI] 10.18502/cjn.v22i2.13340 PMC 바로가기 [Article Type] Review Paper
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis다발성 경화증에서 SARS-CoV-2 백신 접종에 대한 면역 반응: 체계적인 검토/메타 분석Review Published on 2022-08-012022-09-11 Journal: Annals of Clinical and Translational Neurology [Category] COVID19(2023년), SARS, 치료기술, [키워드] Acetate Affect Alemtuzumab anti-CD20 Antibody detection Antibody Response Antibody responses Antibody testing applied CD20 cellular response Cellular responses Cladribine demonstrated dimethyl fumarate Epidemiology fumarate Glatiramer Glatiramer acetate Google Scholar HCs healthy control immune response Immunity inactivated independent interferon Interferon-beta mAb mAbs Meta-analysis meta-analysis and systematic review monoclonal antibody MOOSE mRNA mRNA vaccine mRNA vaccines multivariate logistic regression multivariate logistic regression model Natalizumab not affect observational studies observational study Odds ratio Patient positive predict response SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines searched seroconversion rate seroconversion rates sphingosine-1-phosphate systematic review T cell T cell response T-cell Response T-cell responses Teriflunomide therapy Vaccine vaccine immunity vaccine response Vaccines vector virus [DOI] 10.1002/acn3.51628 PMC 바로가기 [Article Type] Review
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects다발성 경화증 환자에서 SARS-CoV-2 체액 반응의 장기간 지속Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age anti-Spike IgG anti-spike IgG levels appearance benefit BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2-mRNA vaccine booster booster vaccination booster vaccinations Cladribine Cohort comparable coronavirus Coronavirus-19 dimethyl fumarate Disease modifying therapies dose eight evaluated faster fingolimod Fingolimod- Glatiramer Glatiramer acetate groups healthy control healthy controls humoral humoral immune response Humoral persistence Humoral response IgG IgG levels interferon long term mRNA vaccine Multiple multiple sclerosis Natalizumab Ocrelizumab pandemic Patient patients persistence receiving regimen respiratory SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike protein severe acute respiratory syndrome Coronavirus spike Spike protein subject subjects Teriflunomide the SARS-CoV-2 titre variants [DOI] 10.1016/j.msard.2022.103800 PMC 바로가기 [Article Type] Article
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical ViewpointCovid-19 Pandemic 동안 다발성 경화증 치료에 사용되는 약물 : 중요한 관점Article Published on 2022-01-012022-08-31 Journal: Current neuropharmacology [Category] SARS, 치료제, [키워드] Acetate activating acute respiratory distress acute respiratory distress syndrome Alemtuzumab analogue antiviral activity approved ARDS autoimmune disorder Autoimmune disorders caution cellular Cladribine concern COVID-19 COVID-19 infection COVID-19 pandemic cytokine Cytokine storm Defense depleting detrimental dimethyl fumarate disease Disease-modifying therapy drug early stage endothelial example fingolimod fumarate Glatiramer Glatiramer acetate health problem hyperinflammation Hyperinflammatory IFN IFNs immunomodulation interfere interferon Invasion lung Macrophage mechanisms Multiple multiple sclerosis Natalizumab neuroprotection Nrf-2 nucleotide nucleotides Ocrelizumab other organs overcome oxidative stress pathway potential risk Protective public health raised reinforcement respiratory distress risk risk-benefit ratio. Safe SARS-CoV-2 SARS-COV-2 infection sclerosis suggested syndrome Teriflunomide Treatment Viral viral replication [DOI] 10.2174/1570159X19666210330094017 PMC 바로가기 [Article Type] Article
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 VirusArticle Published on 2021-02-242022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] 1:1 3CL 3CL Protease Acetate activity acute respiratory syndrome addition Antiviral binding affinity carried cause cellular characterization China Clinical efficacy clinical study complex component Concentration coronavirus Coronavirus replication COVID COVID-19 COVID-19 pandemic criteria docking Efficacy epithelial cell evaluate factorial design Factors FDA-approved drugs Glatiramer acetate half-maximal inhibitory concentration Health IC50 investigated Nanoparticles outbreak Prevent protease protease inhibition required responses SARS-CoV-2 selected shown sitagliptin target cell TEM the SARS-CoV-2 virus transmission electron microscopy treat VERO-E6 virus were assessed [DOI] 10.3390/ph14030178 PMC 바로가기 [Article Type] Article
A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetateArticle Published on 2020-06-172024-09-04 Journal: IDCases [Category] 대상포진, [키워드] Disseminated zoster Glatiramer acetate herpes zoster immunomodulators shingles [DOI] 10.1016/j.idcr.2020.e00873 PMC 바로가기 [Article Type] Article
Multiple Sclerosis: Pathogenesis and TreatmentArticle Published on 2011-09-012024-09-02 Journal: Current neuropharmacology [Category] 대상포진, [키워드] Glatiramer acetate immune response Interferon-beta multiple sclerosis Pathogenesis [DOI] 10.2174/157015911796557911 PMC 바로가기 [Article Type] Article